Centessa Pharmaceuticals PLC Sponsored ADR $CNTA is Avoro Capital Advisors LLC’s 10th Largest Position

Avoro Capital Advisors LLC raised its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 34.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,555,555 shares of the company’s stock after buying an additional 3,747,475 shares during the quarter. Centessa Pharmaceuticals makes up approximately 3.5% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Avoro Capital Advisors LLC owned about 9.97% of Centessa Pharmaceuticals worth $364,034,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of CNTA. Foresite Capital Management VI LLC raised its position in Centessa Pharmaceuticals by 3.8% in the 4th quarter. Foresite Capital Management VI LLC now owns 1,364,019 shares of the company’s stock valued at $34,114,000 after purchasing an additional 50,000 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Centessa Pharmaceuticals by 321.4% during the 4th quarter. Squarepoint Ops LLC now owns 81,812 shares of the company’s stock worth $2,046,000 after acquiring an additional 62,399 shares in the last quarter. Sofinnova Investments Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $27,618,000. Spruce Street Capital LP acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $1,951,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $314,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.09% of the company’s stock.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several research analyst reports. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their target price for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Trading Down 0.0%

NASDAQ:CNTA opened at $39.75 on Wednesday. The stock’s 50 day moving average price is $39.65 and its 200 day moving average price is $31.04. The company has a market capitalization of $6.15 billion, a PE ratio of -22.21 and a beta of 1.11. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.30 and a 52-week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.